Results 131 to 140 of about 1,197 (187)

Pitolisant for treating patients with narcolepsy

Expert Review of Clinical Pharmacology, 2020
Introduction: Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. Pitolisant is a first-in-class drug acting on histamine 3 receptors and indicated for the treatment of narcolepsy. This article aims to review pitolisant.Areas covered: In
Shuang, Li, Junyi, Yang
openaire   +2 more sources

Evaluating pitolisant as a narcolepsy treatment option

Expert Opinion on Pharmacotherapy, 2020
Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. Treatment of narcolepsy remains challenging and current therapy is strictly symptomatically based.The present manuscript is based on an extensive ...
de Biase S., Pellitteri G., Gigli G. L., Valente M.   +3 more
openaire   +2 more sources

Indikationserweiterung für Pitolisant bei Narkolepsie

InFo Neurologie + Psychiatrie
Yvette C. Zwick
semanticscholar   +2 more sources

Pitolisant: First Global Approval

Drugs, 2016
Pitolisant (Wakix™) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject. Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults. Pitolisant has received a Temporary Authorization of Use in France for this indication in case of treatment failure, intolerance or ...
  +6 more sources

Pitolisant Hydrochloride (Wakix)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Wakix not be reimbursed by public drug plans for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. It is still not known whether Wakix offers any therapeutic benefit over other treatments used for EDS or cataplexy.
openaire   +1 more source

Adjuvant Pitolisant in a Case With Early-Onset Schizophrenia

Clinical Neuropharmacology, 2021
Early-onset schizophrenia is notorious for poor prognostication and treatment refractoriness. Child/adolescent psychiatric population, by virtue of age, is at a heightened risk for cardiometabolic risk of atypical antipsychotics. Available pharmacological options are, sorely, too limited to mitigate this risk.The authors are reporting here on an ...
Ahmed, Naguy, Saxby, Pridmore, Bibi, Alamiri   +2 more
openaire   +2 more sources

The cost utility of pitolisant as narcolepsy treatment

Acta Neurologica Scandinavica, 2020
The cost-effectiveness of available pharmacological treatments for narcolepsy is largely unknown. Available pharmacological treatments are associated with tolerability, abuse, and adherence issues. Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy.
Kristian Bolin, Per‐Åke Niska, Laura Pirhonen, Pontus Wasling, Anne‐Marie Landtblom   +4 more
openaire   +3 more sources

Quantification of Pitolisant: A RP - HPLC study

YMER Digital, 2022
Objective An attempt was made to develop a simple, isocratic and robust reverse phase high performance liquid chromatographic method for Pitolisant. Material and methods An Inertsil octa decyl silane column and photo diode array detector were employed for the quantification of Pitolisant at 268 nm using a mobile phase consisting of acetonitrile and 0.1
Sowjanya Gummadi, Rajya Lakshmi Nimmagadda   +1 more
openaire   +1 more source

0909 Pitolisant Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring

SLEEP, 2023
Abstract Introduction WAKIX (pitolisant) is a potent and highly selective histamine 3 receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Anthony Adamkovic, Padge Montgomery, Michele Roy, Jeffrey Dayno, Kristin Veley   +4 more
openaire   +1 more source

Pharmacokinetics of pitolisant in children and adolescents with narcolepsy

Sleep Medicine, 2020
To evaluate the pharmacokinetic profile and tolerability of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist, in children and adolescents with narcolepsy.This multicenter, open-label, single-dose study of pitolisant 17.8 mg enrolled patients aged 6 through 17 years with a diagnosis of narcolepsy. Blood samples were collected
Lecendreux M., Plazzi G., Franco P., Jacqz-Aigrain E., Robert P., Duvauchelle T., Schwartz J. -C.   +6 more
openaire   +4 more sources